Tag: Prescription Drugs

Displaying 81 - 100 of 134 results.

The Federal Trade Commission today announced its challenge of Mylan Laboratories’ (Mylan) proposed $6.6 billion acquisition of Germany’s E. Merck oHG (Merck), alleging that the transaction would result in significantly reduced competition for the sale and manufacture of five generic drugs in the U...
Commission approval of final consent order: Following a public comment period, the Commission has approved a final consent order in the matter of Actavis Group hf. and Abrika Pharmaceuticals, Inc. The Commission vote approving issuance of the final consent order was 5-0. (FTC File No. 071-0063,...
Testifying today on behalf of the Federal Trade Commission before the U.S. House Subcommittee on Commerce, Trade, and Consumer Protection of the Committee on Energy and Commerce regarding anticompetitive patent settlements in the U.S. pharmaceutical industry, FTC Commissioner Jon Leibowitz said...
The Commission prevented a merger-to-monopoly in the sale of generic isradipine capsules by challenging the proposed $235 million purchase of Abrika Pharmaceuticals, Inc., by the Actavis Group, an international generic pharmaceuticals company. To maintain competition in the market...
The Federal Trade Commission today announced its challenge to the terms of Actavis Group hf.’s (Actavis) proposed acquisition of Abrika Pharmaceuticals, Inc. (Abrika), alleging that the transaction would create a monopoly in the U.S. market for generic isradipine capsules, a drug typically...
The Federal Trade Commission told a subcommittee of the House Judiciary Committee today that patent policy stimulates innovation by providing an incentive to develop and commercialize inventions, but that invalid or questionable patents can increase costs and hinder competition.
The consent order settles charges that Hospira Inc.’s proposed $2 billion acquisition of rival drug manufacturer Mayne Pharma Ltd. Would likely reduce competition and harm consumers. In settling the Commission’s charges, the companies have agreed to divest to Barr Pharmaceuticals,...
To Protect Competition, Companies Must Sell Assets for Five Generic Injectable Drugs The Federal Trade Commission today announced its challenge to Hospira Inc.’s (Hospira) proposed $2 billion acquisition of rival drug manufacturer Mayne Pharma Ltd. (Mayne), along with an agreement and order...
Shows Substantial Increase in the Number of Settlements Involving a Payment to the Generic and a Restriction on Generic Entry The Federal Trade Commission’s Bureau of Competition today issued a summary of agreements filed with the Commission in fiscal year 2006 (ending September 30, 2006) by...
Commission approval of final consent order: Following a public comment period, the Commission has approved the issuance of final consent order in the matter concerning Barr Pharmaceuticals, Inc.’s acquisition of PLIVA d.d. The vote to approve the final consent order, copies of which can be found...
A consent order settled charges that Watson Pharmaceuticals, Inc.’s proposed $1.9 billion acquisition of Andrx Corporation, would have likely led to competitive problems in the markets for 13 generic drug products. Watson was required to end its marketing agreements with Interpham...
The Federal Trade Commission today announced its decision to challenge the terms of Watson Pharmaceuticals, Inc.’s proposed $1.9 billion acquisition of Andrx Corporation, a deal that would have led to competitive problems in the markets for 13 generic drug products. In allowing the deal to proceed...
U.S. District Court Judge Colleen Kollar-Kotelly yesterday entered a final order settling the Federal Trade Commission’s charges that drug company Warner Chilcott’s agreement with Barr Laboratories unlawfully delayed entry of Barr’s generic version of Warner Chilcott’s Ovcon birth control pill.
Protecting competition for the sale of prescription drug Ovcon, the Federal Trade Commission today announced that it has agreed to settle its complaint against Warner Chilcott, which manufactures the branded version of the drug. The settlement will result in lower prices for women who use the...
The consent order settles charges that Barr Pharmaceutical, Inc.’s proposed acquisition of Pliva d.d for approximately $2.5 billion would have eliminated current or future competition between Barr and Pliva in certain markets for generic pharmaceuticals treating depression, high...
The Federal Trade Commission today announced its decision to challenge Barr Pharmaceutical, Inc.’s proposed acquisition of Pliva d.d for approximately $2.5 billion. The FTC’s complaint alleges that the acquisition as originally structured would have eliminated current or future competition between...
The Federal Trade Commission’s Bureau of Competition today issued a summary of agreements filed with the Commission in fiscal year 2005 (ending September 30, 2005) by generic and branded drug manufacturers. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 requires drug...
Commission approval of final consent order: Following a public comment period, the Commission has approved the issuance of a final consent order in the matter concerning Allergan, Inc.’s acquisition of Inamed Corporation. The vote to approve the final order was 4-0, with Commissioner J. Thomas...
The Federal Trade Commission today announced its intention to conduct a study of the use, and likely short- and long-term competitive effects, of authorized generics in the prescription drug marketplace. An authorized generic is chemically identical to a particular brand-name drug, but the brand-...
Botox marketer Allergan, Inc., and the Inamed Corporation will divest the rights to develop and distribute Reloxin, a potential Botox rival, to settle Federal Trade Commission charges that Allergan’s $3.2 billion purchase of Inamed would violate federal antitrust laws. The FTC alleges that...

Pages